We are live on ! Find out more
CPHI icon

China Pharma Holdings
CPHI

6 hedge funds and large institutions have $220K invested in China Pharma Holdings in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 6 → 6 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

32% less capital invested

Capital invested by funds: $322K → $220K (-$102K)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
6
Holders Change
–
Holders Change %
0%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$27.2K
2
VF
Virtu Financial
New York
+$3.83K
3
TSS
Two Sigma Securities
New York
+$2.87K

Top Sellers

Rank Fund Capital Flow
1
PAM
Panagora Asset Management
Massachusetts
-$33K
2
Deutsche Bank
Deutsche Bank
Germany
-$24K
3
Renaissance Technologies
Renaissance Technologies
New York
-$8.06K
4
UBS Group
UBS Group
Switzerland
-$4.51K

CPHI Hedge Fund Activity: Q3 2019 in Review

6 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in China Pharma Holdings (CPHI) for Q3 2019, worth a combined $220K — down 32% from $322K a quarter earlier.

Fund positioning in CPHI was balanced in Q3 2019: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 2 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $27.2K. The largest seller was Panagora Asset Management, exiting entirely with an estimated $33K sold.

  • 6 institutional investors held China Pharma Holdings (CPHI) as of Q3 2019, unchanged from Q2 2019.
  • Funds reported $220K of China Pharma Holdings stock for Q3 2019, down 32% quarter-over-quarter.
  • 2 funds opened new China Pharma Holdings positions in Q3 2019 and 2 closed out, a net change of 0 holders.
  • The largest China Pharma Holdings buyer in Q3 2019 was Citadel Advisors, an estimated $27.2K added.
  • The largest China Pharma Holdings seller in Q3 2019 was Panagora Asset Management, an estimated $33K sold.

Based on aggregated 13F filings for Q3 2019.